Effects of symbiotic (SIMBIOFLORA®) in patients with Crohn´s diseas: a pilot study
DOI:
https://doi.org/10.62827/nb.v23i1.3005Keywords:
Inflammatory bowel diseases; crohn's disease; microbiota.Abstract
Introduction: Inflammatory bowel disease is a generic term that encompasses various pathological entities, the most common of which are non-specific ulcerative colitis and Crohn's disease, which affect the gastrointestinal tract. Some studies have been carried out to test the efficacy of prebiotics, probiotics and synbiotics in improving the clinical condition of individuals with Crohn's disease, mainly because these compounds are known to improve the integrity of the intestinal mucosa and modulate the microbiota and immune-inflammatory responses. Objective: To evaluate the effects of symbiotics on clinical and inflammatory activity in patients with Crohn's disease. Methods: This is an interventional, double-blind study with final participation of 8 adult volunteers, of both sexes, diagnosed with Crohn's disease in inflammatory activity. Results: In the results found It was possible to observe that the use of the daily symbiotic during the period of 2 months resulted in statistically significant improvements (p < 0.05) in relation to the initial condition (pre-intervention) in all the variables studied. Conclusion: The study suggests that the symbiotic may have helped reduce episodes of daily liquid bowel movements, abdominal pain, improved stool consistency and reduced plasma levels of C-reactive protein.
References
World Gastroenterology Organisation [Internet]. Probióticos e prebióticos; fev 2017 [citado 23 ago 2021]. Disponível em: https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-portuguese-2017.pdf
European Federation of Crohn’s & Ulcerative Colitis Associations. World IBD Day 2020 | efcca.org; dez 2019 [citado 13 ago 2020]. Disponível em: https://www.efcca.org/projects/world-ibd-day-2020
Hammer T, et al. The Faroese IBD Study: Incidence of Inflammatory Bowel Diseases Across 54 Years of Population-based Data. J Crohns Colitis. 2016 Aug;10(8):934-42. doi: 10.1093/ecco-jcc/jjw050.
Gasparini RG, Sassaki LY, Saad-Hossne R. Inflammatory bowel disease epidemiology in São Paulo State, Brazil. Clin Exp Gastroenterol. 2018 Oct 30;11:423-429. doi: 10.2147/CEG.S176583.
Selvaratnam S, et al. Epidemiology of inflammatory bowel disease in South America: A systematic review. World J Gastroenterol. 2019 Dec 21;25(47):6866-6875. doi: 10.3748/wjg.v25.i47.6866.
Kotze PG, et al. Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review. Clin Gastroenterol Hepatol. 2020 Feb;18(2):304-312. doi: 10.1016/j.cgh.2019.06.030.
Parente JM, et al. Inflammatory bowel disease in an underdeveloped region of Northeastern Brazil. World J Gastroenterol. 2015 Jan 28;21(4):1197-206. doi: 10.3748/wjg.v21.i4.1197.
Quaresma AB, Kaplan GG, Kotze PG. The globalization of inflammatory bowel disease: the incidence and prevalence of inflammatory bowel disease in Brazil. Curr Opin Gastroenterol. 2019 Jul;35(4):259-264. doi: 10.1097/MOG.0000000000000534.
Zaltman C, et al. Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil. World J Gastroenterol. 2021 Jan 14;27(2):208-223. doi: 10.3748/wjg.v27.i2.208.
Parra RS, et al. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil. World J Gastroenterol. 2019 Oct 14;25(38):5862-5882. doi: 10.3748/wjg.v25.i38.5862.
Lee SH, Kwon JE, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018 Jan;16(1):26-42. doi: 10.5217/ir.2018.16.1.26.
Turpin W, Goethel A, Bedrani L, Croitoru Mdcm K. Determinants of IBD Heritability: Genes, Bugs, and More. Inflamm Bowel Dis. 2018 May 18;24(6):1133-1148. doi: 10.1093/ibd/izy085.
Fiocchi C. Inflammatory bowel disease pathogenesis: where are we? J Gastroenterol Hepatol. 2015 Mar;30 Suppl 1:12-8. doi: 10.1111/jgh.12751.
Murphy K, et al. Probiotics, Prebiotics, and Synbiotics for the Prevention of Necrotizing Enterocolitis. Front Nutr. 2021 Sep 7;8:667188. doi: 10.3389/fnut.2021.667188.
Celiberto LS, et al. Inflammatory bowel disease and immunonutrition: novel therapeutic approaches through modulation of diet and the gut microbiome. Immunology. 2018 Sep;155(1):36-52. doi: 10.1111/imm.12939.
Saez-Lara MJ, Gomez-Llorente C, Plaza-Diaz J, Gil A. The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. Biomed Res Int. 2015; 2015:505878. doi: 10.1155/2015/505878.
Jia K, Tong X, Wang R, Song X. The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis. Medicine (Baltimore). 2018 Dec;97(51):e13792. doi: 10.1097/MD.0000000000013792.
Akutko K, Stawarski A. Probiotics, Prebiotics and Synbiotics in Inflammatory Bowel Diseases. J Clin Med. 2021 Jun 2;10(11):2466. doi: 10.3390/jcm10112466.
Harvey RF, Bradshaw MJ. Measuring Crohn's disease activity. Lancet. 1980 May 24;1(8178):1134-5. doi: 10.1016/s0140-6736(80)91577-9. PMID: 6103463.
Bedani R; Rossi E.A. Microbiota intestinal e probióticos: : Implicações sobre o câncer de cólon. J Port Gastrenterol. 2008. Nov; 16(1): 19-28.
Ribeiro ARP. A Microbiota Intestinal nas Doenças Inflamatórias do Intestino e o Potencial Recurso a Probióticos e Prebióticos [Internet] [Dissertação]. [Faculdade de Medicina da Universidade de Lisboa]; 2016 [cited 2021 Sep 8]. p. 30. Available from: https://repositorio.ul.pt/bitstream/10451/26038/1/AnaRPRibeiro.pdf
Troche JMR, et al. Lactobacillus acidophilus LB: a useful pharmabiotic for the treatment of digestive disorders. Therap Adv Gastroenterol. 2020 Nov 24;13:1756284820971201. doi: 10.1177/1756284820971201.
Huang J, et al. Lactobacillus paracasei R3 protects against dextran sulfate sodium (DSS)-induced colitis in mice via regulating Th17/Treg cell balance. J Transl Med. 2021 Aug 18;19(1):356. doi: 10.1186/s12967-021-02943-x.
Lindsay JO, et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut. 2006 Mar;55(3):348-55. doi: 10.1136/gut.2005.074971.
Waitzberg DL, et al. Effect of synbiotic in constipated adult women - a randomized, double-blind, placebo-controlled study of clinical response. Clin Nutr. 2013 Feb;32(1):27-33. doi: 10.1016/j.clnu.2012.08.010.
Kazemi A, et al. Effect of probiotic and synbiotic supplementation on inflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials. Clin Nutr. 2020 Mar;39(3):789-819. doi: 10.1016/j.clnu.2019.04.004.
Steed H, et al. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther. 2010 Oct;32(7):872-83. doi: 10.1111/j.1365-2036.2010.04417.x.
Taborda A; Tonial ST; Contu PC; Damin DC. A administração perioperatória de simbióticos em pacientes com câncer colorretal reduz a incidência de infecções pós-operatórias: ensaio clínico randomizado duplo-cego. Revista do Colégio Brasileiro de Cirurgiões. Rio de Janeiro. 2017. Dez; 44, (6):567-573. doi: 10.1590/0100-69912017006004.
Ghouri YA, et al. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014 Dec 9;7:473-87. doi: 10.2147/CEG.S27530.
Sivamaruthi BS. A comprehensive review on clinical outcome of probiotic and synbiotic therapy for inflammatory bowel diseases. Asian Pacific Journal of Tropical Biomedicine. 2018 Mar 8: 179-86. doi:10.4103/2221-1691.228000.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Rogério Eduardo Tavares Frade, Ana Paula Ribeiro Paiotti , Sender Jankiel Miszputen (Autor)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution 4.0 que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
Autores têm autorização para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
